Several oncology companies announced key trial milestones this week across the landscape of both blood cancers and solid ...

Vascular toxicity associated with cancer therapies is a leading cause of cardiovascular adverse events in patients with ...

In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses clinical trial fail rates and AI’s ...

Private equity firm THL Partners has agreed to buy a majority stake in Headlands Research, a U.S.-based network of clinical ...

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.

Clinical trials are notorious for being expensive and slow, with rising costs and declining efficiency. According to Bernstein, industry R&D spending grew 44% between 2012 and 2022, while the number ...

The NHS is to trial “robo minders” to keep an eye on dementia patients in their own homes. The technology will allow hospital ...

By Rishika Sadam and Bhanvi Satija (Reuters) -Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting ...

Dr. Hussein Tawbi, who works for MD Anderson in Houston, said there are two things he hopes people take away from the story ...

A phase II clinical trial is larger and is used to determine if the treatment is effective. Depending on the prevalence of the type of cancer the treatment is designed for, up to 100 patients may ...

All trials have some level of risk, but the risk may be small and vary from trial to trial. Both risks and benefits of a clinical trial depend on your cancer and how your treatment is going.

At the end of the day, there is no sure thing in a clinical trial from a patient’s point of view. There are certainly diseases that are life-threatening, and those patients are sometimes willing ...